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Abstract
The therapeutic value of adipose-derived mesenchymal stem cells (Ad-MSCs) for bone regeneration is critically discussed. A
possible reason for reduced osteogenic potential may be an age-related deterioration of the Ad-MSCs. In long term in vitro
culture, epigenomic changes in DNA methylation are known to cause gene silencing, affecting stem cell growth as well as
the differentiation potential. In this study, we observed an age-related decline in proliferation of primary human Ad-MSCs.
Decreased Nanog, Oct4 and Lin28A and increased Sox2 gene-expression was accompanied by an impaired osteogenic
differentiation potential of Ad-MSCs isolated from old donors (.60 a) as compared to Ad-MSCs isolated from younger
donors (,45 a). 5-hydroxymethylcytosine (5 hmC) and 5-methylcytonsine (5 mC) distribution as well as TET gene
expression were evaluated to assess the evidence of active DNA demethylation. We observed a decrease of 5 hmC in Ad-
MSCs from older donors. Incubation of these cells with 5-Azacytidine induced proliferation and improved the osteogenic
differentiation potential in these cells. The increase in AP activity and matrix mineralization was associated with an increased
presence of 5 hmC as well as with an increased TET2 and TET3 gene expression. Our data show, for the first time, a decrease
of DNA hydroxymethylation in Ad-MSCs which correlates with donor-age and that treatment with 5-Azacytidine provides an
approach which could be used to rejuvenate Ad-MSCs from aged donors.
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Introduction
Extensive bone loss after trauma or diseases often results in
delayed or impaired bone healing [1]. Deteriorated bone
regeneration and repair is observed with increasing age of patients
[1,2]. The use of mesenchymal stem cells (MSCs) in tissue
engineering has great potential for a novel approach in acute bone
and cartilage repair, e.g. some pioneer clinical study have already
entered the phase III stage [3].
MSCs are one kind of adult stem cells. In the mechanism of
osteogenesis, MSCs are considered to be one type of progenitor
cells, which are able to proliferate and later on differentiate into
osteogenic cells [4]. Hence, the process of bone regeneration
requires the recruitment, expansion and differentiation of MSCs
[5]. In vitro experiments demonstrated an active self-renewal
capacity and multi-lineage differentiation potential of MSCs [6,7].
MSCs can be isolated from various tissues; most frequently from
adipose tissue and bone marrow. Due to their easy access, low
immune rejection as well as a low risk of tumorigenesis [8,9],
MSCs derived from adipose tissue (Ad-MSCs) could be an ideal
source for patient-specific cell therapy. However, the osteogenic
differentiation potential of these Ad-MSCs has been critically
discussed. Furthermore, it has been reported many times that
adult stem cells, including MSCs, suffer from a decline in stem cell
function with increasing age during long term culture of the cells
[10,11]. The decline observed in the self-renewal capacity, resulted
in an incomplete differentiation into the committed cell lineage
[12].
Epigenetic modification of the genome is considered to be one
of the most important regulatory pathways affecting stem cell
aging. These dynamic changes mainly appear in DNA methyla-
tion and/or chromatin remodeling [13]. Although selected
histone-deacetylase inhibitors could improve osteogenic function
in differentiated MSCs, they are not suitable for use because of
their negative effects on cell proliferation due to DNA damage and
cell-cycle inhibition [14]. Efforts have been made to investigate a
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milder epigenetic modification approach. It has been demonstrat-
ed that DNA demethylation can be induced by 5-Azacytidine, a
DNA methyltransferase (DNMT) inhibitor [15]. In our hands 5-
Azacytidine treatment improved the hepatic differentiation
capacity of Ad-MSCs, in correlation to the DNA demethylation
[16]. Just recently an active DNA-demethylation mechanism was
described in embryonic stem cells. In these cells induction of TET
gene expression promoted the conversion of nuclear 5-methylcyt-
osine (5 mC) to 5-hydroxymethylcytosine (5 hmC) and thus DNA
demethylation, in order to maintain the self-renewal capacity and
the pluripotency state [17].
Thus, aim of the present study was to investigate donor-age-
related changes in the self-renewal of Ad-MSCs as well as their
osteogenic differentiation potential and which role DNA methyl-
ation plays in in this process. Furthermore, we want to investigate
if these donor-age-related changes can be reversed by epigenetic
modifications of the DNA. The stem cell capacity will be assessed
by measuring the expression levels of transcription factors
characteristic for embryonic and induced pluripotent stem cells,
namely, Sox2, Lin28A, Oct4 and Nanog. Cell proliferation will be
determined by the amount of cells stained positive for Ki67. The
osteogenic differentiation potential will be will be defined by
measuring the AP-Activity and matrix mineralization after
differentiation, as well as by measuring the expression levels of
the osteogenic marker gene osteocalcin and the osteogenic
transcription factors Runx2 (early) and osterix (late) [18].
Materials and Methods
Cell culture plastics, collagenase II, phosphate buffered saline
(PBS), fetal calf serum (FCS), DMEM medium and cell culture
supplements were purchased from PAA Laboratories GmbH
(Pasching, Austria). GeneJET RNA Purification Kit, DNase I
(RNase-free) and First Strand cDNA Synthesis Kit were purchased
from Fermantas (Ontario, Canada). Oct-4A (C30A3) Rabbit
mAB, Sox2 (D6D9) Rabbit mAB, Nanog (D73G4) Rabbit mAB,
Lin28A (D84C11) Rabbit mAB and the corresponding secondary
Anti-rabbit IgG, HRP linked Antibody were purchased from Cell
Signaling (Beverly, USA). Ki67 (M-19) Goat pAB was purchased
from Santa Cruz Biotechnology Inc. (Heidelberg, Germany).
Chemicals as well as the Anti-TET2, Anti-TET3 and Anti-
GAPDH Rabbit pAB were purchased from Sigma (Munich,
Germany).
Isolation, Expansion and Characterization of Ad-MSCs
Ad-MSCs were isolated from adipose tissue obtained from
surgery with the written consent of the patients. This study was
specifically approved by the ethical committee of the Universi-
ta¨tsklinikum Tu¨bingen (Reference: 385/2012 B02) who works in
accordance with national regulations and the ICH-GCP guide-
lines. The study was performed according to the declaration of
Helsinki in its newest version. For this study adipose tissue from 23
donors was collected and isolated. Adipose tissue was minced and
washed extensively with PBS before digestion with collagenase II
(0.075% in PBS) at 37uC for 30 to 60 min. The digestion was
stopped with culture medium (DMEM, 10% FCS, 100 U/ml
penicillin, 100 mg/ml streptomycin). After centrifugation (600 g,
10 min) the cell pellet was collected, re-suspended and filtered
through a 70 mM cell strainer. The cells were seeded in flasks
which culture medium. To remove non-attached cells the Ad-
MSCs were washed once with PBS 24 hours after isolation. Ad-
MSCs were expanded in culture medium until passage 3 in order
to minimize the number of contaminating cells in the culture.
Purity of the Ad-MSCs was determined by flow cytometry as
recently published by our group (CD90+, CD105+, CD142,
CD452) [16].
Pre-treatment of Ad-MSCs with 5-Azacytidine
Ad-MSCs from young (,45 a) and old ($60 a) donors were
seeded at a cell density of 10,000 cells/cm2. After cell attachment
the medium was changed to freshly made culture medium
containing 5-Azacytidine (5 mM and 20 mM). After 24 h the 5-
Azacytidine containing culture medium was refreshed for another
24 h (total pre-treatment: 48 h).
Osteogenic Differentiation of Ad-MSCs
For osteogenic differentiation Ad-MSCs from young and old
donors were incubated with osteogenic differentiation medium
(DMEM, 0.5% FCS, 100 U/ml penicillin, 100 mg/ml streptomy-
cin, 100 mM L-Ascorbic Acid-2-phosphate, 10 mM b-glycerol
phosphate, 25 mM HEPES, 1.5 mM CaCl2, 5 mM cholecalciferol)
Table 1. Sequence of primers used in qRT-PCR.
gene bank ID Forward primer (59-.39) reverse primer (59-.39) product length Ta # of cycles
Runx2 NM_001015051.3 TGCCTAGGCGCATTTCAGGTGC GGTGGTGGTGCATGGCGGAA 359 bp 58uC 30*
Osterix NM_152860 CCCAGGCAACACTCCTACTC GGCTGGATTAAGGGGAGCAAA 175 bp 62uC 30*
Osteocalcin NM_199173.3 CCAGCGGTGCAGAGTCCAGC GACACCCTAGACCGGGCCGT 236 bp 56uC 25*
TET1 NM_030625.2 GTAAATGGCCCCAAGTCAGA CAGCTTCTGGGACATTAGCA 211 bp 59uC 40 (qPCR)
TET2 NM_001127208.2 GAGACGCTGAGGAAATACGG TGGTGCCATAAGAGTGGACA 258 bp 59uC 40 (qPCR)
TET3 NM_144993.1 CAGAACGCTGTGATCGTCAT AACTTGCGAGGTGTCTTGCT 263 bp 59uC 40 (qPCR)
NANOG NM_024865.2 AACTGGCCGAAGAATAGCAA ACTGGATGTTCTGGGTCTGG 175 bp 59uC 40 (qPCR)
Oct4 NM_002701.4 AGTGAGAGGCAACCTGGAGA GCCTCAAAATCCTCTCGTTG 180 bp 59uC 40 (qPCR)
Lin28A NM_024674.4 CCGAACCCCATGCGCACGTT TTTGCAGGTGGCTGCGCCAAG 137 bp 59uC 40 (qPCR)
Sox2 NM_003106.3 CATGCACCGCTACGACG CGGACTTGACCACCGAAC 152 bp 62uC 40 (qPCR)
GAPDH NM_002046.4 TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG 87 bp 59uC 40 (qPCR)
Runx2 NM_001015051.3 TGCCTAGGCGCATTTCAGGTGC GGTGGTGGTGCATGGCGGAA 359 bp 58uC 30*
*PCR conditions were optimized with varying template concentrations to be in the quantifiable/linear range of the PCR.
doi:10.1371/journal.pone.0090846.t001
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Figure 1. Declined Proliferation and Osteogenic Differentiation in Ad-MSCs from old donors: Ki67 staining was performed as
proliferation assay. (A) Representative image of a merged immunofluorescent staining for Ki67 (red) and nuclei (blue) from young and old Ad-
MSCs. (B) Quantification of Ki67-positive Ad-MSCs (N= 3, n = 5/age group) points to a reduced proliferation in aged Ad-MSCs. After 14 days of
osteogenic differentiation of young and old Ad-MSCs osteoblasts function was assessed by measuring (C) AP activity (each group: N= 7, n = 3), (D–G)
matrix mineralization and (H–J) gene expression changes. Matrix mineralization was determined by (D & F) von Kossa (each group: N = 5, n = 3) and (E
& G) Alizarin red staining (each group: N = 6, n = 3). mRNA levels of the osteogenic transcription factors (H) Runx2 and (I) Osterix, as well as the
osteogenic marker (J) Osteocalcin were determined by semi-quantitative RT-PCR (each group: N = 5, n = 3). GAPDH was used for normalization. *p,
0.05, **p,0.01, ***p,0.001 (student’s t-test).
doi:10.1371/journal.pone.0090846.g001
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for 14 days. The differentiation medium was changed every 3–4
days.
Alkaline Phosphatase (AP) Activity
In order to determine the AP activity, the differentiated cells
were incubated with substrate solution (2 mg/ml 4-Nitrophenyl
phosphate disodium salt hexahydrate, 50 mM glycine, 1 mM
MgCl2, 100 mM Tris, pH=10.5) for 120 min. The subsequent 4-
Nitrophenol production in the supernatant was measured photo-
metrically at l=405 nm with a FLUOstar Omega Plate reader
(BMG Labtech, Offenburg, Germany), and normalized to relative
cell numbers measured by Sulforhodamine B Staining as described
before [19,20].
Matrix Mineralization
Matrix mineralization was assessed by Alizarin red and von
Kossa staining. For both stainings cells were fixed with 99%
ethanol for 1 h at 220uC. For alizarin red staining cells were
incubated with 0.5% Alizarin red S solution (PH=4.0) for 20 min,
then washed extensively with tap water to remove unbound stain.
For von Kossa staining cells were incubated with 3% AgNO3
solution for 30 min, then washed extensively with tap water,
exposed to 5% sodium carbonate (in 10% formaldehyde) solution
for 2 min, followed by an incubation in 5% sodium-thiosulfate
solution for 5 min in order to develop color. For both staining
methods the plates were first scanned to obtain an overview image,
than images with the light microscope were taken. Alizarin red
staining was quantified photometrically (l=562 nm) with a
FLUOstar Omega Plate reader, after resolving the stain with
10% cetylpyridinium chloride solution. The von Kossa staining
was quantified densitometrically (Pixel intensity) with the Image J.
1.45 s software (National Institutes of Health, USA).
Immunofluorescence Staining
Ad-MSCs were plated onto cover slips and treated according to
the experimental setup. Cells were fixed with 4% paraformalde-
hyde solution for 15 min at RT and then washed with PBS. For
permeabilization, cells were incubated with 0.5% Triton-X-
100 PBS solution for 30 min at RT. To denature the DNA cells
were incubated with 4 M HCl for 15 min at RT. After washing
with PBS unspecific binding sites were blocked with blocking
buffer (10% FCS, 0.1% Tween-20 in PBS) for 1 h at RT. Then
cells were incubated with primary antibody solution anti-5 hmC
rabbit polyclonal IgG (Active Motif, CA, USA), anti-5 mC mouse
monoclonal IgG, (Active Motif, CA, USA) or anti-Ki67 goat
polyclonal IgG (Santa Cruz Biotechnology, CA, USA) diluted
1:100 in PBS solution containing 1% FCS and 0.1% Tween-20 for
2 h at RT. After washing three times with PBS cells were
incubated with secondary antibody solution (ALEXA-fluor anti-
bodies (Invitrogen, NY, USA) diluted 1:400 in PBS solution
containing 1% FCS, 0.1% Tween-20 for 1 h at RT. Nuclei were
counterstained by incubation with Hoechst 33342 solution (2 mg/
Figure 2. Altered expression of pluripotency genes in Ad-MSCs from old donors. Basal expression levels of pluripotency genes were
determined in Ad-MSCs from young and old donors (each group: N= 6, n = 3). mRNA levels of (A) Lin28A (2 donors from the young Ad-MSCs had to
be excluded from the data set, due to artefacts in the melting curve), (B) Oct4, (C) Nanog and (D) Sox2 were determined by qRT-PCR. (E) Expression
changes of Lin28A, Oct4, Nanog and Sox2 were confirmed on the protein level by Western blot analysis (N = 3/group). For both techniques GAPDH was
used for normalization. *p,0.05, **p,0.01 (student’s t-test).
doi:10.1371/journal.pone.0090846.g002
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ml in PBS) for 20 min at RT. After a final washing step with PBS,
the stained cells were mounted with mounting medium (Fluor-
omount G, Southern Biotech, NJ, USA). Images of the staining
were taken with an EVOS fluorescence microscope (AMG, USA)
under standardized condition, processed and analyzed with Image
J 1.45 s software [21].
Quantification of Gene Expression
Total RNA from Ad-MSCs was extracted with GeneJET RNA
Purification Kit. 2–3 mg of the total RNA was digested with
DNase I in order to remove remaining genomic DNA. cDNA was
synthesized using the First Strand cDNA Synthesis Kit. Gene
expression changes were analyzed either by conventional RT-
PCR or by qRT-PCR depending on the amount of target mRNA
present in the sample. PCR protocols were optimized for each
gene separately to be in a quantifiable (linear) range in our
samples.
For quantitative real time PCR (qRT-PCR) a standardized
amount of template cDNA was tested for the expression level of
each target gene (primer sequences are listed in Table 1) using
SYBR Green qPCR (Finnzym, Vantaa, Finnland) and the Step
One Plus Real-Time PCR System (Applied Biosystems, CA,
USA). GAPDH was used as endogenous control. Relative changes
in gene expression were calculated using the DDCT Method with
either untreated young cells (changes with age) or untreated age
matched cells (changes du to 5-Azacytidine treatment) as
reference.
For semi-quantitative (conventional) RT-PCR a standardized
amount of template cDNA was tested for the expression level of
each target gene (primer sequences are listed in Table 1) using
KAPA Fast ready mix (Peqlab, Erlangen, Germany). Products,
resolved by gel electrophoresis in a 2% (w/v) agarose gel, were
visualized with ethidiumbromide. Densitometric analysis of signals
was performed using ImageJ software (NIH, Bethesda, USA). Pixel
Intensities of the PCR signal were normalized to GAPDH using a
normalization factor (multiple of the average GAPDH signal).
Relative changes in gene expression were calculated with either
untreated young cells (changes with age) or untreated age matched
cells (changes du to 5-Azacytidine treatment) as reference.
Western Blot
Cells were lyzed in freshly prepared ice-cold RIPA buffer
(50 mM TRIS, 250 mM NaCl, 2% Nonidet-P40, 2.5 mM EDTA,
0.1% SDS, 0.5% DOC, protease and phosphatase inhibitors,
Figure 3. Distribution of 5-hydroxymethylcytosine (5 hmC) and 5-methylcytosine (5 mC) in Ad-MSCs. Basal mRNA levels of (A) TET2 and
(B) TET3 were determined by qRT-PCR in Ad-MSCs from young and old donors (each group: N = 6, n = 3). (C) Expression changes of TET2 and TET3
were confirmed on the protein level by Western blot analysis (N = 3/group). For both techniques GAPDH was used for normalization. (D) Young and
old Ad-MSCs (each group: N= 3, n = 5) were stained for 5-hydroxymethylcytosine (5 hmC/red) and 5-methylcytosine (5 mC/green). Cell nuclei were
counterstained with Hoechst 33342 (blue). (E&F) For quantification 5 hmC or 5 mC positive nuclei were counted. *p,0.05, **p,0.01 (student’s t-test).
doi:10.1371/journal.pone.0090846.g003
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pH=7.2). Protein concentration was determined by micro-Lowry
[22]. 50 mg total protein were separated by SDS-PAGE and
transferred to nitrocellulose membranes (Roth, Karlsruhe, Ger-
many). Unspecific binding sites were blocked with 5% BSA in
TBST solution (25 mM Tris, 137 mM NaCl, 2.7 mM KCl,
0.05% Tween-20, pH=7.4) for 1 h at RT. After overnight
incubation with primary antibodies diluted 1:1,000 in TBST at
4uC, membranes were incubated with the corresponding HRP-
labeled secondary antibodies (1:10,000 in TBST) for 2 h at RT.
For signal development membranes were incubated for 1 min with
ECL substrate solution (1.25 mM luminol, 0.2 mM p-coumaric
acid, 0.03% H2O2 in 100 mM TRIS, pH=8.5). Chemilumines-
cent signals were detected with a CCD camera (INTAS,
Go¨ttingen, Germany). GAPDH was used as loading control.
Densitometric analysis of signals was performed using ImageJ
software (NIH, Bethesda, USA).
Statistical Analysis
Results are expressed as box blot (Whisker’s: min to max) or bar
chart (mean 6 SEM) of at least 3 independent experiments
(biological replicates, N$3) measured as triplicates or more
(technical replicates, n$3). The precise of replicates for each
experiment is given in the figure legends. Individual data sets were
compared by Student’s t test or one way ANOVA analysis (Prism
5.04, GraphPad Software, CA, USA), with consideration of the
sample distribution. p,0.05 was set as the minimum level of
significance.
Results
Ad-MSCs from Elderly Donors showed Impaired
Proliferation and Osteogenic Differentiation Capacity
In order to assess the proliferation capacity of the cells a Ki67
staining was performed. Expression of Ki67 was significantly lower
in Ad-MSCs isolated from aged donors as compared to Ad-MSCs
isolated from younger donors (figure 1A & B), representing an
impaired proliferation capacity of Ad-MSCs from elderly donors.
In order to evaluate the differentiation potential, Ad-MSCs were
differentiated for 14 days in the presence of osteogenic differen-
tiation medium. As osteogenic markers alkaline phosphatase (AP)
activity, matrix mineralization and relative gene expression of
Runx2, osterix and osteocalcin were determined after the differenti-
ation process. In comparison to Ad-MSCs from young donors, Ad-
MSCs from old donors exhibited a significantly lower AP activity
(figure 1C) and a significant weaker matrix mineralization, as
determined by von Kossa (figure 1D & F) and Alizarin red staining
(figure 1E & G). Increased expression of the early osteogenic
transcription factor Runx2 and reduced expression of the late
osteogenic transcription factor osterix suggest a delay in osteogenic
differentiation in Ad-MSCs from aged donors. This is supported
by reduced expression of osteocalcin, the most abundant non-
collagenous protein in bone (figure 1H–J).
Gene Expression of Pluripotency Markers Demonstrated
Age-related Differences in Ad-MSCs
The differentiation potential was evaluated by relative gene
expression levels of the pluripotency markers Nanog, Oct4, Lin28A
and Sox2 by qRT-PCR. GAPDH was used as endogenous control.
Expression of Lin28A was significantly lower in Ad-MSCs from
elderly donors (figure 2A). Similarly, expression of Oct4 was
reduced in Ad-MSCs from aged donors (figure 2B). Furthermore,
expression of Nanog was significantly lower in Ad-MScs from
elderly donors (figure 2C). Conversely, expression levels of Sox2
were significantly elevated in Ad-MSCs from aged donors
(figure 2D). The observed expression changes were confirmed on
protein level by Western blot (figure 2E).
TET Gene Expression and 5 mC/5 hmC Distribution in
Ad-MSCs from Young and Old Donors
Members of the TET family (TET1-3) are reported to actively
regulate DNA methylation. Therefore, we determined relative
gene expression levels of TET1, TET2 and TET3 by qRT-PCR.
GAPDH was used as endogenous control. Expression of TET1
was near/below the detection limit in Ad-MSCs from young and
elderly donors. Therefore, no significant difference could be
detected (data not shown). Expression levels of TET2 were
Figure 4. 5-Azacytidine treatment increased TET2 and TET3 gene expression. Young and old Ad-MSCs were treated with 5 mM 5-Azacytidine
for 48 h. mRNA levels of (A) TET2, (B) TET3, (E) Sox2, (F) Lin28A (2 donors from the young Ad-MSCs had to be excluded from the data set, due to
artefacts in the melting curve), (G) Oct4 and (H) Nanog were determined by qRT-PCR (N= 6, n = 3/age group). (I) Expression changes of TET2, TET3,
Lin28A, Oct4, Nanog and Sox2 were confirmed on the protein level by Western blot analysis (Representative figure for N = 2/group). GAPDH was used
for normalization. Data are presented as relative expression changes (log10) of 5-Azacytidine treated Ad-MSCs compared to the corresponding
untreated Ad-MSCs. Distribution of 5-hydroxymethylcytosine (5 hmC) and 5-methylcytosine (5 mC) in the 5-Azacytidine treated and untreated Ad-
MSCs was determined by immunofluorescent staining (N= 3, n = 5/age group). Cell nuclei were counterstained with Hoechst 33342. For
quantification (D) 5 hmC and (E) 5 mC positive nuclei were counted. Data are represented as log10 (fold of control). *p,0.05, **p,0.01, ***p,0.001
as compared to untreated cells (student’s t-test).
doi:10.1371/journal.pone.0090846.g004
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Figure 5. 5-Azacytidine treatment improves osteogenic differentiation of Ad-MSCs from old donors. Ki67 staining was performed to
assess the proliferation capacity of young and old Ad-MSCs after treatment with 5 mM 5-Azacytidine for 48 h. (A) Representative image of a merged
immunofluorescent staining for Ki67 (red) and nuclei (blue). (B) Quantification of Ki67-positive Ad-MSCs (N= 3, n = 5/age group) points to an induced
proliferation in aged Ad-MSCs after treatment with 5-Azacytidine. Young and old Ad-MSCs were pre-treated with 5 mM 5-Azacytidine for 48 h before
Rejuvenation of Aged Ad-MSCs with 5-Azacytidine
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significantly elevated in Ad-MSCs from aged donors (figure 3A).
TET3 expression levels were not changed between the two age
groups (figure 3B). The observed expression changes were
confirmed on protein level by Western blot (figure 3C). Genomic
distribution of 5-hydroxymethylcytosine (5 hmC) and 5-methyl-
cytosine (5 mC) in Ad-MSCs from young and old donors was
evaluated by immunofluorescence staining (5 hmC: red, 5 mC:
green) in order to assess the DNA methylation status. Nuclei were
counterstained with Hoechst 33342 (blue) (figure 3D). The 5 mC-
positive fraction was significantly higher in the Ad-MSCs from old
donors than in the Ad-MSCs from young donors (figure 3E). The
5 hmC-positive fraction was significantly lower in the Ad-MSCs
from old donors than in the Ad-MSCs from young donors
(figure 3F).
5-Azacytidine Treatment Induced Expression of TET2 and
TET3 while Increasing Nuclear 5 hmC Levels
5-Azacytidine is a well characterized DNA-methyltransferase
inhibitor. In order to evaluate the effect of 5-Azacytidine on the
DNA methylation status, relative gene expression levels of TET1,
TET2 and TET3 were determined by qRT-PCR in Ad-MSCs
from young and old donors treated for 48 h with 5 mM 5-
Azacytidine. GAPDH was used as endogenous control. After 5-
Azacytidine treatment TET1 expression was still near the
detection limit in Ad-MSCs from both young and old donors,
where no significant difference could be detected (data not shown).
In both age groups, TET2 expression levels were significantly
increased by 5-Azacytidine treatment (figure 4A). Similarly, TET3
expression levels were increased by 5-Azacytidine treatment in
both age groups, with more pronounced changes in Ad-MScs from
aged donors (figure 4B). Expression changes of TET2 and TET3
due to 5-Azacytidine treatment were confirmed by Western blot
on the protein level (data not shown). Genomic distribution of
5 hmC and 5 mC, in Ad-MSCs from old donors, was strongly
affected by 5-Azacytidine treatment, as determined by immuno-
fluorescence staining. The 5 hmC-positive fraction was signifi-
cantly increased in Ad-MSCs from old donors after treatment with
5-Azacytidine (figure 4C). This resulted in a significant decrease in
the 5 mC-positive fraction in Ad-MSCs from old donors after
treatment with 5-Azacytidine (figure 4D). Consequently relative
expression levels of the pluripotency markers Nanog, Oct4, Lin28A
and Sox2 were changed by 5-Azacytidine treatment, as determined
by qRT-PCR. Expression levels of Sox2 were significantly
decreased by 5-Azacytidine treatment only in Ad-MSCs from
aged donors (figure 4E). Expression of Lin28A was significantly
induced by 5-Azacytidine treatment in Ad-MSCs from elderly
donors (figure 4F). Expression of Oct4 was significantly induced by
5-Azacytidine treatment in Ad-MSCs from both age groups
(figure 4G). In contrary to Lin28A expression of Nanog was induced
by 5-Azacytidine treatment only in Ad-MScs from young donors
(figure 4H). On the protein level, pluripotency markers showed a
comparable regulation due to 5-Azacytidine treatment (figure 4I).
5-Azacytidine Pre-treatment Improved Proliferation and
Osteogenic Differentiation of Ad-MSCs from Aged
Donors
In the following experiments we wanted to analyze of the
reduction in DNA methylation by 5-Azacytidine improves the
proliferation and the osteogenic differentiation capacity of aged
Ad-MSCs. Following the treatment of Ad-MSCs from old donors
with 5 mM 5-Azacytidine for 48 h significantly more cells were
Ki67-positive (1.3-fold, p,0.01), representing an improved prolif-
eration. Conversely, no improvement of the proliferation was
observed in Ad-MSCs from young donors following the treatment
with 5 mM 5-Azacytidine for 48 h (figure 5A & B). After pre-
treatment with 5 mM 5-Azacytidine for 48 h, Ad-MSCs from aged
donors were differentiated for 14 days in the presence of
osteogenic differentiation medium. As osteogenic markers alkaline
phosphatase (AP) activity, matrix mineralization and relative gene
expression of Runx2, osterix and osteocalcin were determined after the
differentiation process. Pre-treatment with 5-Azacytidine im-
proved AP activity (figure 5C) only in Ad-MSCs from elderly
donors. Similarly, matrix mineralization was enhanced by 5-
Azacytidine treatment only in Ad-MSCs from aged donors as
determined by von Kossa (figure 5D & F) and Alizarin red staining
(figure 5E & G). Expression levels of the early osteogenic
transcription factor Runx2 were significantly reduced by 5-
Azacytidine treatment only in Ad-MSCs from aged donors
(figure 5H). Conversely, expression levels of the late osteogenic
markers osterix and osteocalcin were significantly induced by 5-
Azacytidine treatment only in Ad-MSCs from elderly donors
(figure 5I & J).
Discussion
Stem cell functions include self-renewal and multipotency or
even pluripotency. In particular, self-renewal of stem cells does not
only include proliferation, but also the maintenance of their
differentiation potential after cell division [23]. Our results
demonstrate a decreased proliferation rate of Ad-MSCs from
aged donors as well as an impaired osteogenic differentiation
potential, as characterized by a declined AP activity, a weaker
mineralization of extracellular matrix and reduced expression of
late osteogenic marker genes osterix and osteocalcin in the
differentiated cells from elderly donors, which was accompanied
by a strong DNA methylation. Increased global DNA methylation
status is a well-established phenomenon that has been observed in
many aged adult tissue/cell types [24].
Our preliminary research has shown that 5-Azacytidine
treatment significantly reduces the global level of DNA methyl-
ation [16]. In the past, the demethylation effect of 5-Azacytidine
was described as a cause of direct or indirect inhibition of the
DNA methyltranferases (DNMTs) [25]. This theory resembles
mainly the passive DNA demethylation process. Recently, more
active mechanisms of DNA demethylation have been uncovered
[26]. TET proteins mediated conversion of 5 mC to 5 hmC was
shown to play a crucial role in active demethylation of DNA [27].
Here, we have presented for the first time, that Ad-MSCs display
reduced levels of 5 hmC during aging. With the conversion of
osteogenic differentiation was induced. In the differentiated cells osteoblasts function was assessed by measuring (C) AP activity (N= 7, n = 3/age
group), (D–G) matrix mineralization and (H–J) gene expression changes. Matrix mineralization was determined by (D & F) von Kossa (N= 4, n = 3/age
group) and (E & G) Alizarin red staining (N= 6, n = 3/age group). mRNA levels of the osteogenic transcription factors (H) Runx2 and (I) Osterix, as well
as the osteogenic marker (J) Osteocalcin were determined by semi-quantitative RT-PCR (N= 5, n = 3/age group). GAPDH was used for normalization.
All data are presents as relative changes (log10) of 5-Azacytidine pre-treated differentiated Ad-MSCs compared to the corresponding differentiated
Ad-MSCs without pre-treatment.*p,0.05, **p,0.01, ***p,0.001 as compared to differentiated Ad-MSCs without pre-treatment (student’s t-test).
doi:10.1371/journal.pone.0090846.g005
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5 mC to 5 hmC by TET proteins [17], further modifications can
occur in order to launch the active DNA demethylation, i.e.
oxidation to 5-formylcytosine (5 fC) and 5-carbonylcytosine
(5 caC). 5 caC eventually will be removed by a base excision
pathway and thus will be replaced with unmethylated cytosine
[26]. Thus, the finding of reduced 5 hmC levels in aged Ad-MSCs
could account for a DNA hypermethylation pattern in these [16]
and other adult cell types [24]. This is further supported by the
finding that 5 hmC has been proven to act like a poor substrate for
DNMT1 recognition [28]. In this way, it is also able to take part in
the passive DNA demethylation by preventing factors that interact
with methylcytosine [26].
Most interestingly, treatment of aged Ad-MSCs with the
DNMT-inhibitor 5-Azacytidine not only reduced DNA methyla-
tion passively [16] but also actively, by inducing TET expression
and nuclear 5 hmC. In contrast to embryonic stem cells, where
only TET1 plays a key role in DNA hydroxylation [17,29], in aged
Ad-MSCs TET2 and TET3 expression was significantly induced
by 5-Azacytidine treatment. Controversially to the hypothesis that
increased TET levels lead to an accumulation of 5 hmC, aged Ad-
MSCs show slightly increased basal expression levels of TET2.
However, this hypothesis is based on work with embryonic stem
cells [17,29], where TET1 is the master regulator. In our cells from
both age groups, however, TET1 expression is negligible as it is
close to/below the detection limit. Furthermore, it is still unclear,
whether expression and activity of DNA methyl-transferases is
altered with aging as suggested by Casillas and co-workers [30].
The work of Koh et al reports that expression of TET1 and
TET2 is strongly dependent on the expression of Oct4, while
TET3 expression negatively correlates with Sox2 expression levels
[31]. In Ad-MSCs from elderly donors expression of the
pluripotency-associated genes Nanog, Oct4 and Lin28A was strongly
reduced, while Sox2 expression was induced. After 5-Azacytidine
Oct4 and Lin28A expression significantly increased and Sox2
expression was significantly decreased in aged Ad-MSCs. Consid-
ering the data from Koh et al this might explain the observed
increase in expression of TET2 and TET3 after 5-Azacytidine
treatment in Ad-MSCs from aged donors [31]. Why TET2
expression was not affected by 5-Azacytidine treatment in Ad-
MSCs from young donors might be explained by the interaction of
the different pluripotency factors itself [32], as in this age group 5-
Azacytidine treatment induced the expression of Oct4 and Nanog
but not Lin28A.
Oct4 and Nanog are described as core transcription factors for the
regulation and the maintenance of pluripotency in embryonic stem
cells [33,34]. It has been reported that Lin28A is able to promote
cell proliferation in embryonic stem cells and breast tumor cells
[35,36]. Our data imply that the observed age-related loss of
capacity for self-renewal and differentiation could be triggered by
the reduced expression of these and other genes controlling stem
cell renewal. This implication was supported by the work of Tsai
et al, showing, that with increasing time in culture, Nanog and Oct4
expression as well as osteogenic differentiation capacity decreases
in MSCs [37]. Lin28A and Oct4 may play a special role in this
regulatory mechanism as the treatment with 5-Azacytidine, which
strongly induced the expression of Lin28A and Oct4, was able to
improve proliferation and osteogenic differentiation in Ad-MSCs
from elderly donors. Basal expression levels of the pluripotency
factor Sox2 was very low in young Ad-MSCs, which is in line with
other publications [38]. Interestingly, basal Sox2 expression levels
were significantly elevated in Ad-MSCs from elderly donors and
decreased with the 5-Azacytidine treatment. The decline in Sox2
expression after 5-Azacytidine treatment may be pivotal for the
improved osteogenic differentiation, as there are reports showing
that depletion of Sox2 promotes osteogenic differentiation in a
great variety of stem cells [39,40,41,42].
In our aged Ad-MSCs 5-Azacytidine not only induced the cells
proliferation but also accelerated their osteogenic differentiation.
This is shown by a significant increase in AP activity and matrix
mineralization. Supporting this hypothesis the early osteogenic
transcription factor Runx2 is reduced in favor for a faster induction
of the late osteogenic marker genes osterix and osteocalcin [18].
Conclusion
Summarizing, our data suggest that DNA methylation plays a
crucial role in adult stem cell aging, as DNA methylation increases
with donor age in Ad-MSCs. We could show that 5-Azacytidine, a
small molecule inhibitor for DNMTs, not only passively but also
actively promotes DNA demethylation in Ad-MSCs from aged
donors. This balanced the expression levels of pluripotency genes
and improved the osteogenic differentiation potential, thus
rejuvenating aged Ad-MSCs.
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